Overview

Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)

Status:
Completed

Trial end date:
2009-07-01

Target enrollment:

Participant gender:

Summary

The aim of the present study was to evaluate the use of drotaverine hydrochloride versus hyoscine-N-butylbromide in reducing duodenal motility during diagnostic and therapeutic ERCP.

Phase:

Phase 3

Details

Lead Sponsor:

Changhai Hospital

Treatments:

Butylscopolammonium Bromide
Drotaverin
Papaverine
Scopolamine
Scopolamine Hydrobromide